Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders (Q34177643)

31 July 2017

1 reference

title

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders (English)

1 reference

31 July 2017

0 references

Gerard J Marek

1

1 reference

31 July 2017

Linda L Carpenter

series ordinal

2

1 reference

31 July 2017

Christopher J McDougle

series ordinal

3

1 reference

31 July 2017

Lawrence H Price

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

13 September 2002

1 reference

31 July 2017

Neuropsychopharmacology

1 reference

31 July 2017

28

1 reference

31 July 2017

402-412

1 reference

31 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300057

31 July 2017

0 references

cites work

Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Sleep disorders in patients with severe mental depression: Double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon®)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A molecular and cellular theory of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Systematic review and guide to selection of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Serotonin 5-HT1D receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Serotonergic mediation of DRL 72s behavior: receptor subtype involvement in a behavioral screen for antidepressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Mirtazapine treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Olanzapine and obsessive-compulsive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Effects of tryptophan depletion in drug-free adults with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Pharmacology of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Clinical Effects of the 5-HT1A Partial Agonists in Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Thalamic midline cell populations projecting to the nucleus accumbens, amygdala, and hippocampus in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Attenuation of 5-HT1A and 5-HT2 but not 5-HT1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Involvement of 5-HT1C-receptors in drug-induced penile erections in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Mirtazapine augmentation in the treatment of refractory depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

A double-blind study comparing idazoxan and bupropion in bipolar depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Gepirone in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Tranylcypromine plus risperidone for treatment-refractory major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

High 5HT2A receptor occupancy in M100907-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300057

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300057

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference